NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio reorganization. Intellia is a clinical-stage gene editing company ...

Intellia Therapeutics has said it will reduce its headcount by 27% this year and shelve early-stage R&D programmes as it puts its resources behind two priority drug candidates. The specialist in ...

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA) in the last three months. The table below offers a ...

As you can see from the chart above the percentage of shares that are sold short for Intellia Therapeutics has grown since its last report. This does not mean that the stock is going to fall in ...

Intellia Therapeutics, Inc. and Editas Medicine, Inc. are undergoing organizational restructuring and pipeline prioritization, aiming to optimize resources and extend the cash runway until 2027 ...

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

In this article, we are going to take a look at where Intellia Therapeutics Inc. (NASDAQ:NTLA) stands against the other stocks in Cathie Wood's portfolio. Cathie Wood is one of Wall Street's most ...

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...